Clinical Study
Vitamin D Receptor Gene BsmI Polymorphism in Polish Patients with Systemic Lupus Erythematosus
Table 4
Relationship between BsmI genotypes and clinical manifestation or laboratory profiles of SLE.
| | | GG | GA | AA | Total |
*
|
| | Malar rash | 14/33 | 13/20 | 6/9 | 33/62 | 0.216 | | Discoid rash (DLE) | 4/33 | 1/20 | 0/9 | 5/62 | 0.549 | | Photosensitivity | 6/33 | 0/20 | 3/9 | 9/62 | 0.145 | | Oral ulcer | 5/33 | 0/20 | 1/9 | 6/62 | 0.171 | | Arthritis/arthralgia | 30/33 | 18/20 | 9/9 | 57/62 | 1.000 | | Serositis | 3/33 | 1/20 | 1/9 | 5/62 | 0.840 | | Renal disorder | 5/33 | 2/20 | 1/9 | 8/62 | 0.876 | | Neuropsychiatric disorder | 7/33 | 4/20 | 2/9 | 13/62 | 1.000 | | Hematologic disorder | | | | | | | (i) Anemia | 9/33 | 2/20 | 2/9 | 13/62 | 0.348 | | (ii) Leukopenia | 16/33 | 6/20 | 6/9 | 28/62 | 0.172 | | (iii) Lymphopenia | 1/33 | 1/20 | 0/9 | 2/62 | 1.000 | | (iv) Thrombocytopenia | 9/33 | 2/20 | 0/9 | 11/62 | 0.135 | | Immunologic disorder | | | | | | | (i) Anti-dsDNA | 9/33 | 1/20 | 2/9 | 12/62 | 0.124 | | (ii) Anti-Sm | 0/33 | 0/20 | 0/9 | 0/62 | 1.000 | | ANA presence | 29/33 | 18/20 | 8/9 | 55/62 | 1.000 |
|
|
Freeman-Halton extension of Fisher's exact test and Fisher’s exact test.
|
